Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orthofix Medical Inc.OFIX · Entity 1975 | President, Global Limb Recon | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orthofix Medical Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,919 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 150 · Balance 50,919 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. F2: Includes 36,028 previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.
F2: Includes 36,028 previously reported restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 19,586 |
Reported balance
After 2020-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-11 · Other · Disposed 31,951 · Balance 19,586 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 31,951 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2: Includes 6,843 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 12,743 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 7,821 |
Reported balance
After 2020-11-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 7,821 F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4: Includes 6,843 Shares issuable upon vesting of the Wright RSUs and 978 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 7,821 · Balance 0 F5: See Exhibit 99.1. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 18,506 |
Reported balance
After 2020-11-11 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2020-11-11 · Grant · Acquired 18,506 · Balance 18,506 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 18,506 · Balance 0 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-11 · Disposition to issuer · Disposed 14,385 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-11 · Disposition to issuer · Disposed 12,278 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-11 · Disposition to issuer · Disposed 12,363 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-11 · Disposition to issuer · Disposed 23,897 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-11 · Disposition to issuer · Disposed 13,217 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-11 · Disposition to issuer · Disposed 13,217 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.06 · Expires 2024-05-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-11-11 · Disposition to issuer · Disposed 6,113 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.93 · Expires 2023-05-14 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-11-11 · Disposition to issuer · Disposed 6,588 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2022-05-09 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-11-11 · Disposition to issuer · Disposed 828 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.04 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2020-11-11 · Disposition to issuer · Disposed 3,760 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 31,951 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Includes 6,843 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 12,743 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer.
F4: Includes 6,843 Shares issuable upon vesting of the Wright RSUs and 978 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.
F5: See Exhibit 99.1.
F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2018 Filed Jan 16, 2018 16:25 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 100 | $24.41 | $2,441.00 |
DisclosureSEC source: 0001235802-18-000012 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,176 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 434 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 16:08 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 100 | $22.80 | $2,280.00 |
DisclosureSEC source: 0001235802-17-000170 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,094 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 252 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 16:36 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 100 | $24.36 | $2,436.00 |
DisclosureSEC source: 0001235802-17-000169 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremitites 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,194 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 252 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 19:28 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 100 | $26.69 | $2,669.00 |
DisclosureSEC source: 0001235802-17-000162 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,294 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 252 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 16:05 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 100 | $26.77 | $2,677.00 |
DisclosureSEC source: 0001235802-17-000148 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,394 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 252 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 18:33 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 12,363 | $0.00 Strike: $27.86 | $0.00 |
DisclosureSEC source: 0001235802-17-000130 · primary_doc.xml · derivative · entry 2 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,363 Underlying: Ordinary Shares · 12,363 shares Expires 2027-07-25 F3 · derivative.exercise_date: This option vests with respect to 25% of the shares on July 25, 2018 and with respect to the remaining 75% of such shares over the three-year period thereafter in 36 as nearly equal as possible monthly installments. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 18:33 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 4,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-17-000130 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,494 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan, 4,188 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 252 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 16:33 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | SaleOrdinary Shares, par value EUR 0.03 per share | 1,682 | $27.09 | $45,565.38 |
DisclosureSEC source: 0001235802-17-000065 · primary_doc.xml · nonDerivative · entry 1 Fisher Patrick · CIK 0001677842 · President, Lower Extremities 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,130 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.22, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 10,805 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 76 ordinary shares acquired under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.